Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Devine

Showing results (71-80 of 178) with videos related to

Pageof 18
Sort By:
Cancer|December 11, 2019
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 studyJonathon B Cohen, Lai Wei, Kami J Maddocks, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 28, 2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials NetworkGinna G Laport, Juan Wu, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)C Alan Howard, Marcelo A Fernandez-Vina, Frederick R Appelbaum, et al.
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Transplantation and Cellular Therapy|October 12, 2020
Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023Nosha Farhadfar, Linda J Burns, Tatenda Mupfudze, et al.
British Journal of Haematology|July 27, 2012
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemiaSamantha M Jaglowski, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
Blood Advances|March 23, 2021
Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AMLFiras El Chaer, Uma Borate, Rémy Duléry, et al.
Clinical Pharmacokinetics|April 17, 2013
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host diseaseMing J Poi, Craig C Hofmeister, Jeffrey S Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2014
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cellsJianhong Chu, Shun He, Youcai Deng, et al.
Pageof 18

Showing results (71-80 of 178) with videos related to

Sort By:
Pageof 18
Cancer|December 11, 2019
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 studyJonathon B Cohen, Lai Wei, Kami J Maddocks, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 28, 2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials NetworkGinna G Laport, Juan Wu, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)C Alan Howard, Marcelo A Fernandez-Vina, Frederick R Appelbaum, et al.
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Transplantation and Cellular Therapy|October 12, 2020
Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023Nosha Farhadfar, Linda J Burns, Tatenda Mupfudze, et al.
British Journal of Haematology|July 27, 2012
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemiaSamantha M Jaglowski, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
Blood Advances|March 23, 2021
Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AMLFiras El Chaer, Uma Borate, Rémy Duléry, et al.
Clinical Pharmacokinetics|April 17, 2013
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host diseaseMing J Poi, Craig C Hofmeister, Jeffrey S Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2014
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cellsJianhong Chu, Shun He, Youcai Deng, et al.
Pageof 18